https://www.selleckchem.com/pr....oducts/Fulvestrant.h
Tamoxifen-based hormone therapy is central for the treatment of estrogen receptor positive (ER+ ) breast cancer. However, the acquired tamoxifen resistance, typically co-exists with hypoxia, remains a major challenge. We aimed to develop a non-invasive, targeted ultrasound imaging approach to dynamically monitory of tamoxifen resistance. After we assessed acquired tamoxifen resistance in 235 breast cancer patients and a list of breast cancer cell lines, we developed poly(lactic-co-glycolic acid)-poly(ethylene glycol)-carbonic anhydr
Like
Comment
Share
